Gilead Sciences News

CytoDyn Inc. , a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013.

John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company at the conference on Tuesday, June 18 at 10:35 a.m. Eastern Time.

Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Wells Fargo Securities 2013 Healthcare Conference in Boston.

The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.

Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib , an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy.

It carries out the discovery, development and marketing of novel therapeutics for life threatening diseases.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

Gilead's investigational nucleotide hepatitis C virus polymerase inhibitor sofosbuvir has been given priority review status by the U.S. Food and Drug Administration, with a target date in early December, the company announced last week.

Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a "buy" rating on shares of Gilead Sciences in a research note to investors on Friday, June 7th.

Gilead Sciences Inc.'s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV's spread.

There was intensive insider selling in EnerNOC in August 2010 when the stock was trading above $33 .

Dr. Glover was most recently President and Chief Executive Officer of YM BioSciences, an oncology drug development company acquired by Gilead Sciences for "Dr. Glover is a natural fit to round out our Board of Directors, adding a wealth of relevant strategic and operational knowledge," said , Ph.D., President and Chief Executive Officer of MEI ... (more)

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Goldman Sachs 34th Annual Healthcare Conference in Rancho Palos Verdes, California.

Jun. 7, 2013-- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.

Despite the recent weakness in the overall market, the red-hot biotech sector has remained strong for the most part.

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.

The US biotechnology industry, which is a speculative growth market, is going up as investors are becoming optimistic about its growth and investing big sums into biotech companies.

As the CFA and CIO of Wedgewood Partners Inc., Guru David Rolfe has been managing Wedgewood's portfolio for over 18 years.

Coming up on five years after the recession threatened to tear the heart out of the industry, biotech companies in the Bay Area continue to struggle in many ways.

GILD shareholders have witnessed an increase in hedge fund sentiment of late. There were 53 hedge funds in our database with GILD positions at the end of the previous quarter.